Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? [Yahoo! Finance]
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: Yahoo! Finance
TCR Bispecific candidates IMA402 and IMA401, which demonstrated objective responses in challenging solid tumor indications. Early findings revealed treatment responses in patients with melanoma and ovarian carcinoma resistant to prior therapies, underpinning the company's focus on expanding its immunotherapy pipeline. We'll explore how these encouraging clinical trial results for IMA402 and IMA401 impact Immatics' investment narrative and pipeline outlook. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. What Is Immatics' Investment Narrative? For anyone considering Immatics, conviction depends heavily on believing in the clinical promise of TCR Bispecific therapies and the company's ability to translate data into long-term value. Th
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Biotech Immatics to raise $125M through ordinary share offering [Seeking Alpha]Seeking Alpha
- Immatics Announces $125 Million Underwritten Offering [Yahoo! Finance]Yahoo! Finance
- Immatics Announces $125 Million Underwritten OfferingGlobeNewswire
- Immatics (NASDAQ:IMTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Immatics (NASDAQ:IMTX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
IMTX
Earnings
- 11/17/25 - Beat
IMTX
Sec Filings
- 12/5/25 - Form 424B5
- 12/5/25 - Form 424B5
- 11/17/25 - Form 6-K
- IMTX's page on the SEC website